3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
10184
Triple Negative Breast Neoplasms
1046
Neoplasms
574
Ovarian Neoplasms
564
Neoplasm Metastasis
515
Colorectal Neoplasms
473
Carcinoma, Non-Small-Cell Lung
468
Prostatic Neoplasms
440
Lung Neoplasms
433
Pancreatic Neoplasms
312
Melanoma
299
Stomach Neoplasms
295
Breast Neoplasms, Male
257
Motor Activity
252
Colonic Neoplasms
238
Uterine Cervical Neoplasms
227
Endometrial Neoplasms
223
Head and Neck Neoplasms
218
Carcinoma, Intraductal, Noninfiltrating
217
Carcinoma, Renal Cell
192
Squamous Cell Carcinoma of Head and Neck
181
Sarcoma
177
Urinary Bladder Neoplasms
159
Esophageal Neoplasms
155
Brain Neoplasms
155
Breast Carcinoma In Situ
154
Lymphedema
148
Fatigue
136
Carcinoma, Ovarian Epithelial
134
Small Cell Lung Carcinoma
130
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Breast
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled